valproic acid has been researched along with EBV Infections in 6 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) was combined with gemcitabine (GCb) to stimulate EBV reactivation, followed by antiviral treatment with ganciclovir (GCV)." | 1.46 | Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model. ( de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M, 2017) |
| " Treatment was commenced with the HDACi sodium valproate (VPA) in combination with the anti-viral nucleoside analogue ganciclovir (GCV)." | 1.36 | Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. ( Corbett, G; Gandhi, MK; Jones, K; Nourse, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Okoye, I | 1 |
| Xu, L | 1 |
| Motamedi, M | 1 |
| Parashar, P | 1 |
| Walker, JW | 1 |
| Elahi, S | 1 |
| Novalić, Z | 1 |
| Verkuijlen, SAWM | 1 |
| Verlaan, M | 1 |
| Eersels, JLH | 1 |
| de Greeuw, I | 1 |
| Molthoff, CFM | 1 |
| Middeldorp, JM | 1 |
| Greijer, AE | 1 |
| Hsu, CL | 1 |
| Kuo, YC | 1 |
| Huang, Y | 1 |
| Huang, YC | 1 |
| Lui, KW | 1 |
| Chang, KP | 1 |
| Lin, TL | 1 |
| Fan, HC | 1 |
| Lin, AC | 1 |
| Hsieh, CH | 1 |
| Lee, LY | 1 |
| Wang, HM | 1 |
| Li, HP | 1 |
| Chang, YS | 1 |
| Jones, K | 1 |
| Nourse, J | 1 |
| Corbett, G | 1 |
| Gandhi, MK | 1 |
| Iwata, S | 1 |
| Saito, T | 1 |
| Ito, Y | 1 |
| Kamakura, M | 1 |
| Gotoh, K | 1 |
| Kawada, J | 1 |
| Nishiyama, Y | 1 |
| Kimura, H | 1 |
| Feng, WH | 1 |
| Kenney, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for valproic acid and EBV Infections
| Article | Year |
|---|---|
Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Ly | 2020 |
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Bar | 2017 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; C | 2015 |
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
Topics: Antiviral Agents; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Histone Deacetylase Inh | 2010 |
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line; Cel | 2012 |
Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Epstein-Barr Virus Infections; Gene Exp | 2006 |